Real-world registry of the durable Angiolite fluoroacrylate polymer-based sirolimus-eluting stent: the EPIC02 – RANGO study

ABSTRACT Introduction and objectives: After the positive pre-clinical and clinical results with Angiolite, a cobalt-chromium sirolimus-eluting stent, we decided to analyze its performance in a non-selected, real-world population: the RANGO registry. Methods: We conducted an observational, prospectiv...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Armando Pérez de Prado, Raymundo Ocaranza-Sánchez, Fernando Lozano Ruiz-Poveda, José Moreu Burgos, Raquel Álvarez Ramos, Alberto Rodrigues, Pablo Aguar, Eduardo Pinar, Vicente Peral, Fermín Sainz Laso, José Ramón Rumoroso, Alfonso Torres, Manel Sabaté, Ramiro Trillo Nouche
Formato:	article
Lenguaje:	EN ES
Publicado:	Permanyer 2021
Materias:	Sirolimus-eluting-stent Durable fluoropolymer Observational study Efficacy Safety Stent thrombosis Medicine R
Acceso en línea:	https://doaj.org/article/2d2664193b654726b0c43d5f1ed79edc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2d2664193b654726b0c43d5f1ed79edc
record_format	dspace
spelling	oai:doaj.org-article:2d2664193b654726b0c43d5f1ed79edc2021-11-16T10:22:38ZReal-world registry of the durable Angiolite fluoroacrylate polymer-based sirolimus-eluting stent: the EPIC02 – RANGO study10.24875/RECICE.M210002232604-7322https://doaj.org/article/2d2664193b654726b0c43d5f1ed79edc2021-11-01T00:00:00Zhttps://recintervcardiol.org/en/index.php?option=com_content&view=article&id=682https://doaj.org/toc/2604-7322ABSTRACT Introduction and objectives: After the positive pre-clinical and clinical results with Angiolite, a cobalt-chromium sirolimus-eluting stent, we decided to analyze its performance in a non-selected, real-world population: the RANGO registry. Methods: We conducted an observational, prospective, multicenter registry of patients with different clinical indications. All consecutive patients treated with percutaneous coronary intervention with, at least, 1 Angiolite stent and who gave their informed consent were included. The registry primary endpoint was the occurrence of target lesion failure (TLF) at 6, 12, and 24 months defined as cardiovascular death, myocardial infarction (MI) related to target vessel, and clinically driven target lesion revascularization. The secondary endpoints were the individual components of the primary endpoint, major adverse cardiovascular events (MACE: all-cause mortality, any MI, or any revascularization), and stent thrombosis. We describe the 2-year clinical results of the RANGO study in the entire population, in those who only received Angiolite stents, and in 2 predefined subgroups: diabetics and patients with small-vessels (≤ 2.5mm). Results: 646 patients (426 of them only received Angiolite stents) with a high-risk profile were recruited: prevalence of previous MI (18.4%), previous coronary revascularization (23.4%), clinical presentation as ST-segment elevation MI (23.1%), and multivessel disease (47.8%). At the 2-year follow-up, the rates of TLF, MACE, and stent thrombosis were 3.4%, 9.6%, and 0.9%, respectively. Similar results were observed among patients treated with Angiolite stents only: TLF, 3.1%; MACE, 8.0%; thrombosis, 0.7%. The rates were not significantly different for the diabetic (TLF, 3.0%; MACE, 14.1%; thrombosis, 1.0%), and small-vessel subgroups (TLF, 4.3%; MACE, 12.1%; thrombosis, 0%). Conclusions: In conclusion, the results of this observational registry on the use of Angiolite in a real-world population, including a high-risk population, corroborate the excellent results observed in previous studies, up to a 2-year follow-up. An extended 5-year follow-up is planned to discard the occurrence of late events.Armando Pérez de PradoRaymundo Ocaranza-SánchezFernando Lozano Ruiz-PovedaJosé Moreu BurgosRaquel Álvarez RamosAlberto RodriguesPablo AguarEduardo PinarVicente PeralFermín Sainz LasoJosé Ramón RumorosoAlfonso TorresManel SabatéRamiro Trillo NouchePermanyerarticleSirolimus-eluting-stent Durable fluoropolymer Observational study Efficacy Safety Stent thrombosisMedicineRENESREC: Interventional Cardiology (English Ed.), Vol 3, Iss 4, Pp 258-266 (2021)
institution	DOAJ
collection	DOAJ
language	EN ES
topic	Sirolimus-eluting-stent Durable fluoropolymer Observational study Efficacy Safety Stent thrombosis Medicine R
spellingShingle	Sirolimus-eluting-stent Durable fluoropolymer Observational study Efficacy Safety Stent thrombosis Medicine R Armando Pérez de Prado Raymundo Ocaranza-Sánchez Fernando Lozano Ruiz-Poveda José Moreu Burgos Raquel Álvarez Ramos Alberto Rodrigues Pablo Aguar Eduardo Pinar Vicente Peral Fermín Sainz Laso José Ramón Rumoroso Alfonso Torres Manel Sabaté Ramiro Trillo Nouche Real-world registry of the durable Angiolite fluoroacrylate polymer-based sirolimus-eluting stent: the EPIC02 – RANGO study
description	ABSTRACT Introduction and objectives: After the positive pre-clinical and clinical results with Angiolite, a cobalt-chromium sirolimus-eluting stent, we decided to analyze its performance in a non-selected, real-world population: the RANGO registry. Methods: We conducted an observational, prospective, multicenter registry of patients with different clinical indications. All consecutive patients treated with percutaneous coronary intervention with, at least, 1 Angiolite stent and who gave their informed consent were included. The registry primary endpoint was the occurrence of target lesion failure (TLF) at 6, 12, and 24 months defined as cardiovascular death, myocardial infarction (MI) related to target vessel, and clinically driven target lesion revascularization. The secondary endpoints were the individual components of the primary endpoint, major adverse cardiovascular events (MACE: all-cause mortality, any MI, or any revascularization), and stent thrombosis. We describe the 2-year clinical results of the RANGO study in the entire population, in those who only received Angiolite stents, and in 2 predefined subgroups: diabetics and patients with small-vessels (≤ 2.5mm). Results: 646 patients (426 of them only received Angiolite stents) with a high-risk profile were recruited: prevalence of previous MI (18.4%), previous coronary revascularization (23.4%), clinical presentation as ST-segment elevation MI (23.1%), and multivessel disease (47.8%). At the 2-year follow-up, the rates of TLF, MACE, and stent thrombosis were 3.4%, 9.6%, and 0.9%, respectively. Similar results were observed among patients treated with Angiolite stents only: TLF, 3.1%; MACE, 8.0%; thrombosis, 0.7%. The rates were not significantly different for the diabetic (TLF, 3.0%; MACE, 14.1%; thrombosis, 1.0%), and small-vessel subgroups (TLF, 4.3%; MACE, 12.1%; thrombosis, 0%). Conclusions: In conclusion, the results of this observational registry on the use of Angiolite in a real-world population, including a high-risk population, corroborate the excellent results observed in previous studies, up to a 2-year follow-up. An extended 5-year follow-up is planned to discard the occurrence of late events.
format	article
author	Armando Pérez de Prado Raymundo Ocaranza-Sánchez Fernando Lozano Ruiz-Poveda José Moreu Burgos Raquel Álvarez Ramos Alberto Rodrigues Pablo Aguar Eduardo Pinar Vicente Peral Fermín Sainz Laso José Ramón Rumoroso Alfonso Torres Manel Sabaté Ramiro Trillo Nouche
author_facet	Armando Pérez de Prado Raymundo Ocaranza-Sánchez Fernando Lozano Ruiz-Poveda José Moreu Burgos Raquel Álvarez Ramos Alberto Rodrigues Pablo Aguar Eduardo Pinar Vicente Peral Fermín Sainz Laso José Ramón Rumoroso Alfonso Torres Manel Sabaté Ramiro Trillo Nouche
author_sort	Armando Pérez de Prado
title	Real-world registry of the durable Angiolite fluoroacrylate polymer-based sirolimus-eluting stent: the EPIC02 – RANGO study
title_short	Real-world registry of the durable Angiolite fluoroacrylate polymer-based sirolimus-eluting stent: the EPIC02 – RANGO study
title_full	Real-world registry of the durable Angiolite fluoroacrylate polymer-based sirolimus-eluting stent: the EPIC02 – RANGO study
title_fullStr	Real-world registry of the durable Angiolite fluoroacrylate polymer-based sirolimus-eluting stent: the EPIC02 – RANGO study
title_full_unstemmed	Real-world registry of the durable Angiolite fluoroacrylate polymer-based sirolimus-eluting stent: the EPIC02 – RANGO study
title_sort	real-world registry of the durable angiolite fluoroacrylate polymer-based sirolimus-eluting stent: the epic02 – rango study
publisher	Permanyer
publishDate	2021
url	https://doaj.org/article/2d2664193b654726b0c43d5f1ed79edc
work_keys_str_mv	AT armandoperezdeprado realworldregistryofthedurableangiolitefluoroacrylatepolymerbasedsirolimuselutingstenttheepic02rangostudy AT raymundoocaranzasanchez realworldregistryofthedurableangiolitefluoroacrylatepolymerbasedsirolimuselutingstenttheepic02rangostudy AT fernandolozanoruizpoveda realworldregistryofthedurableangiolitefluoroacrylatepolymerbasedsirolimuselutingstenttheepic02rangostudy AT josemoreuburgos realworldregistryofthedurableangiolitefluoroacrylatepolymerbasedsirolimuselutingstenttheepic02rangostudy AT raquelalvarezramos realworldregistryofthedurableangiolitefluoroacrylatepolymerbasedsirolimuselutingstenttheepic02rangostudy AT albertorodrigues realworldregistryofthedurableangiolitefluoroacrylatepolymerbasedsirolimuselutingstenttheepic02rangostudy AT pabloaguar realworldregistryofthedurableangiolitefluoroacrylatepolymerbasedsirolimuselutingstenttheepic02rangostudy AT eduardopinar realworldregistryofthedurableangiolitefluoroacrylatepolymerbasedsirolimuselutingstenttheepic02rangostudy AT vicenteperal realworldregistryofthedurableangiolitefluoroacrylatepolymerbasedsirolimuselutingstenttheepic02rangostudy AT ferminsainzlaso realworldregistryofthedurableangiolitefluoroacrylatepolymerbasedsirolimuselutingstenttheepic02rangostudy AT joseramonrumoroso realworldregistryofthedurableangiolitefluoroacrylatepolymerbasedsirolimuselutingstenttheepic02rangostudy AT alfonsotorres realworldregistryofthedurableangiolitefluoroacrylatepolymerbasedsirolimuselutingstenttheepic02rangostudy AT manelsabate realworldregistryofthedurableangiolitefluoroacrylatepolymerbasedsirolimuselutingstenttheepic02rangostudy AT ramirotrillonouche realworldregistryofthedurableangiolitefluoroacrylatepolymerbasedsirolimuselutingstenttheepic02rangostudy
_version_	1718426533263048704

Real-world registry of the durable Angiolite fluoroacrylate polymer-based sirolimus-eluting stent: the EPIC02 – RANGO study

Ejemplares similares